Scientists from the Terasaki Institute for Biomedical Innovation have developed a nanoengineered bioink with improved bonding and cross-linking capabilities for 3D bioprinting of tumor models.
NHS sets sights on ending cervical cancer by 2040 with HPV vaccine drive – Pharmaceutical Technology
Share this article Currently, the NHS offers MSD’s Gardasil 9 to both boys and girls aged 12 to 13 years and to those from higher-risk